Fetal fibronectin detection for preterm birth prediction.

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Clinical Diagnostics

Background:

• Preterm birth remains a leading cause of perinatal morbidity and mortality.
• Accurate prediction of preterm birth is crucial for timely intervention.
• Fetal fibronectin (fFN) is a biomarker investigated for preterm birth prediction.

Purpose of the Study:

• To evaluate the predictive performance of fetal fibronectin (fFN) testing for preterm birth in pregnant women.
• To assess the impact of lower genital tract infections on fFN test accuracy.
• To determine the clinical utility of fFN testing in managing preterm birth risk.

Main Methods:

• A cohort of 124 pregnant women was studied.
• Vaginal secretions were analyzed for fFN using quick test strips.
• Samples were also tested for bacterial vaginosis, mycoplasma, and chlamydia.
• Delivery data at various gestational ages (7 days, 14 days, 34 weeks, 37 weeks) were collected and analyzed.

Main Results:

• Eighteen cases (14.5%) experienced preterm birth, with 10 delivering before 34 weeks.
• fFN testing demonstrated high negative predictive values (up to 100% at 7 days) but lower positive predictive values (ranging from 6.9% to 20.7%).
• Lower genital tract infections were found to significantly impact the positive predictive value of fFN tests (P < 0.05).

Conclusions:

• fFN testing shows promise for preterm birth prediction, particularly with its high negative predictive value.
• The positive predictive value of fFN is limited by the presence of lower genital tract infections.
• fFN-positive results warrant timely clinical evaluation and management to reduce adverse perinatal outcomes.